Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Trimmed by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 755,112 shares of the biopharmaceutical company’s stock after selling 92,570 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Regeneron Pharmaceuticals were worth $793,804,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Sachetta LLC grew its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares in the last quarter. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $26,000. Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. Finally, Family Firm Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $754.87 on Thursday. The firm’s 50-day moving average is $921.45 and its 200-day moving average is $1,022.55. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market cap of $82.95 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 2.89 and a beta of 0.15.

Analysts Set New Price Targets

REGN has been the topic of several research analyst reports. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Citigroup began coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price objective for the company. Morgan Stanley reduced their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, Royal Bank of Canada reduced their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.